Abstract 4283
Background
SM-88 (D,L-alpha-metyrosine; racemetyrosine [USAN]) is a relatively non-toxic, targeted therapy based on the Warburg Effect. It may be well suited for pancreas cancer because of its ability to penetrate tumors and tolerability in compromised patients.
Methods
Subjects progressed on at least one line of chemotherapy were randomized to receive either 460 mg/d or 920 mg/d single agent SM-88 administered with low doses of methoxsalen, phenytoin, and sirolimus (MPS) in the dose selecting stage of this trial. The primary endpoint is response rate by BICR.
Results
As of April 2019, 49 subjects with stage IV pancreatic ductal adenocarcinoma with radiographically documented progressive disease were enrolled and randomized. Mean age was 66 (45 – 85); median of 2 prior lines (1 – 5+); baseline median CA19.9 was 2,674 (0.8 – 651,696). There were 22 disease related SAEs before drug treatment, including 6 Grade 5 events. SM-88 was well tolerated with only four treatment-related Grade 3/4 adverse events in two subjects (and no treatment-related Grade 5 events). 94% of treated subjects (46/49) experienced a total 365 AEs, with only 17% (63/365) at least possibly treatment related. CTCs at baseline were detected in 100% (mean 138 cells/4 ml) and fell in 79% (23/29) evaluable subjects from 153 to a nadir of 54 cells/4 ml (median reduction 63% [18% - 100%]). 12% (4/33) evaluable subjects showed CA19.9 declines (-8% to –97% decline within 3 months), three of which also showed CTC declines. Subjects have remained on treatment a median of 6.9 wks (1.7 – 23.1). While progressive upon entry, 21% (8 of 38 evaluable subjects) displayed stable disease or better at 2 months or beyond. Of the 38 evaluable subjects, 42% (16/38) were alive at 4 months post randomization, and 24% (9/38) were alive at 6 months, which parallels carry over effect previously observed with SM-88. EORTC QLQ-C30, -PAN26, and correlative assays were obtained including leptin, genomics, and NLR.
Conclusions
SM-88 demonstrated unconfirmed monotherapy effect with no meaningful toxicity in a preliminary assessment of this ongoing trial. With additional follow up, dose and patient populations will be selected for expansion.
Clinical trial identification
NCT03512756.
Editorial acknowledgement
Legal entity responsible for the study
Tyme Inc.
Funding
Tyme Inc.
Disclosure
A. Ocean: Advisory / Consultancy: Tyme Inc. M. Noel: Advisory / Consultancy: Tyme Inc. A. Wang-Gillam: Advisory / Consultancy: Tyme Inc. S. Pant: Advisory / Consultancy: Tyme Inc. G. Del Priore: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: Tyme Inc. V. Picozzi: Advisory / Consultancy: Tyme Inc. All other authors have declared no conflicts of interest.
Resources from the same session
2674 - Multicenter Phase I Trial of Trastuzumab Emtansine (T-DM1) in Combination with Non-Pegylated Liposomal Doxorubicin (NPLD) in HER2[+] Metastatic Breast Cancer (MBC). THELMA Study
Presenter: Elena López-Miranda
Session: Poster Display session 2
Resources:
Abstract
1398 - Phase 1 study of liposomal formulation of eribulin (E7389-LF) in patients (pts) with advanced solid tumors: primary results of dose-escalation part
Presenter: Noboru Yamamoto
Session: Poster Display session 2
Resources:
Abstract
5818 - Polo-like Kinase 1 inhibitor onvansertib synergizes with paclitaxel in breast cancer carrying p53 mutation
Presenter: Antonio Giordano
Session: Poster Display session 2
Resources:
Abstract
5927 - Phase 1b study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173).
Presenter: Robert Wesolowski
Session: Poster Display session 2
Resources:
Abstract
1695 - Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: results from the AGMT_MBC-Registry
Presenter: Simon Peter Gampenrieder
Session: Poster Display session 2
Resources:
Abstract
1742 - Clinical profile and outcome of HER2 positive breast cancer patients with brain metastases treated with HER2 targeted therapy: Real world experience.
Presenter: Prabhat Bhargava
Session: Poster Display session 2
Resources:
Abstract
1846 - Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: results of single arm phase IV COMACHI study
Presenter: Norikazu Masuda
Session: Poster Display session 2
Resources:
Abstract
5385 - Anti HER-2 Therapies and Left Ventricular Dysfunction The Renaissance Study
Presenter: ANDRES DANIELE
Session: Poster Display session 2
Resources:
Abstract
3320 - Safety and efficacy of T-DM1 in 128 patients with advanced HER2+ breast cancer: The Royal Marsden experience.
Presenter: Nicolò Battisti
Session: Poster Display session 2
Resources:
Abstract
4540 - Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): challenges in assessing effectiveness of treatment sequencing in the real world (RW)
Presenter: Thibaut Sanglier
Session: Poster Display session 2
Resources:
Abstract